Barbara-Jean Anne Bormann-Kennedy insider trades: Xeris Biopharma Holdings (XERS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Barbara-Jean reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | XERS | ↓ Sell | 15,000 | $7.09 | $106K | Direct | Dec 15, 2025 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other XERS insiders
Open-market trades in the last 12 months
About Barbara-Jean Anne Bormann-Kennedy's insider trades
Barbara-Jean Anne Bormann-Kennedy is a director at Xeris Biopharma Holdings (XERS). Since Dec 12, 2025, Barbara-Jean has reported no open-market purchases and 1 sale worth $106K on SEC Form 4. In the last 12 months: 1 sale ($106K).
Their filings also include grants and awards (8 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every XERS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.